ESBL-producing Enterobacteriaceae by Centers for Disease Control and Prevention (U.S.) & National Center for Emerging Zoonotic and Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. Antibiotic Resistance Coordination and Strategy Unit .
EXTENDED-SPECTRUM 
BETA-LACTAMASE (ESBL) PRODUCING 
 ENTEROBACTERIACEAE 
THREAT LEVEL SERIOUS
197,400
Estimated cases 
in hospitalized 
patients in 2017 
9,100
Estimated 
deaths in 2017 
$1.2B
Estimated attributable 
healthcare costs in 2017
ESBL-producing Enterobacteriaceae (a family of different types of bacteria) are a concern in healthcare 
settings and the community. They can spread rapidly and cause or complicate infections in healthy people.
WHAT YOU NEED TO KNOW
 ■ ESBLs are enzymes that break down commonly used 
antibiotics, such as penicillins and cephalosporins, 
making them ineffective. 
 ■ ESBL-producing Enterobacteriaceae often cause 
infections in otherwise healthy people. About one-
quarter of patients with these infections had no known 
underlying health conditions. 
 ■ Antibiotic options to treat ESBL-producing 
Enterobacteriaceae infections are limited. Healthcare 
providers often have to use intravenous (IV) 
carbapenem antibiotics to treat infections that used  
to be treated with oral antibiotics.
CASES OVER TIME
CDC and partners are working to assess and address why 
cases of ESBL-producing Enterobacteriaceae have increased 
since 2012. 
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ESBL-PRODUCING ENTEROBACTERIACEAE 
RESISTANCE SPREADS QUICKLY 
The Enterobacteriaceae family includes Escherichia 
coli (E. coli). Certain strains (types) of E. coli, such as 
ST131, have quickly spread in the community and among 
healthcare settings. These strains often cause more 
severe infections and spread more easily. Additionally, 
a particular ESBL enzyme, called CTX-M, appears to 
be spreading in the United States and around the 
world. The CTX-M enzyme can be shared through DNA 
(genes) between different Enterobacteriaceae species. 
When CTX-M and ST131 combine, they are a dangerous 
combination that can rapidly spread resistance.  
In many cases, even common infections caused 
by ESBL-producing germs require more complex 
treatments. Instead of taking oral antibiotics at 
home, patients with these infections might require 
hospitalization and IV carbapenem antibiotics. The  
more we rely on carbapenem antibiotics, the greater  
the possibility of resistance developing to this  
important class of antibiotics.
WHERE INFECTIONS CAN HAPPEN 
Almost half of ESBL-producing Enterobacteriaceae infections 
occur in people who have not had recent inpatient healthcare 
exposure or an invasive medical procedure. These infections 
are called community-associated infections.
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Data shows infections by epidemiological classification (the setting where patients 
most likely got the infection based on clinical information).
ONLINE RESOURCES
About Healthcare-associated Infections
www.cdc.gov/hai
CDC Healthcare-associated Infections Guidelines and 
Recommendations 
www.cdc.gov/infectioncontrol/guidelines/index.html
This fact sheet is part of CDC’s 2019 Antibiotic Resistance Threats Report.  
The full report, including data sources, is available at www.cdc.gov/DrugResistance/Biggest-Threats.html.
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